JCO: Professor Qiang Li found that a PRO-based active management model can reduce the symptom burden and complications of lung cancer patients after discharge

On January 8, 2022, the team of Professor Li Qiang and Professor Shi Qiuling from Sichuan Cancer Hospital delivered the strongest voice in China! The results of a multi-center randomized controlled clinical study (CN-PRO-Lung 2 study) led by the team were published in the Journal of Clinical Oncology, the world's top oncology journal

Full text link https://ascopubs.

This study aimed to evaluate the effectiveness and feasibility of symptom management based on Patient-Reported Outcome (PRO) in the early postoperative period for lung cancer .

Patients with preoperative, clinically diagnosed lung cancer were randomly assigned 1:1 to receive postoperative PRO-based symptom management (intervention group) or usual care (control group)

The primary outcome was the number of symptom-threshold events (any target symptom score ≥4) at discharge, using PP analysis

A total of 166 patients were included in the study, 83 in the intervention group and 83 in the control group

It is reported that this study is a clinical study initiated by the researchers and is organized and implemented by the PRO research team of the Thoracic Surgery Center of Sichuan Cancer Hospital

This study is the first in the world to verify that the PRO-based active symptom monitoring-warning-feedback whole-process management model can accelerate the postoperative recovery of lung cancer patients, and the patient satisfaction is high; for the first time in the Chinese cultural background and medical system, it is proved that the PRO-based initiative The management model is effective and feasible in the surgical field, which is beneficial to clinical promotion

The research has formed high-level evidence-based medical evidence for PRO for postoperative management of lung cancer, which will provide new ideas for changing the "passive" management of patients during hospitalization, "free-range" status after discharge, and solving "difficulty in seeing a doctor".

The publication of this result will promote the application of a new clinical indicator of patient-reported outcomes (PRO) in the clinical research and clinical practice of malignant tumors in China, and will also establish Sichuan Cancer Hospital's leading position in the field of clinical application of PRO at home and abroad

Author bio

Contributed by: Sichuan Cancer Hospital

On January 8, 2022, the team of Professor Li Qiang and Professor Shi Qiuling from Sichuan Cancer Hospital delivered the strongest voice in China! The results of a multi-center randomized controlled clinical study (CN-PRO-Lung 2 study) led by the team were published in the Journal of Clinical Oncology, the world's top oncology journal

Full text link https://ascopubs.

The primary outcome was the number of symptom-threshold events (any target symptom score ≥4) at discharge, using PP analysis

A total of 166 patients were included in the study, 83 in the intervention group and 83 in the control group

It is reported that this study is a clinical study initiated by the researchers and is organized and implemented by the PRO research team of the Thoracic Surgery Center of Sichuan Cancer Hospital
.
It took five years from team formation, research design
, project establishment, platform construction, research implementation to publication of results .

This study is the first in the world to verify that the PRO-based active symptom monitoring-warning-feedback whole-process management model can accelerate the postoperative recovery of lung cancer patients, and the patient satisfaction is high; for the first time in the Chinese cultural background and medical system, it is proved that the PRO-based initiative The management model is effective and feasible in the surgical field, which is beneficial to clinical promotion
.

The research has formed high-level evidence-based medical evidence for PRO for postoperative management of lung cancer, which will provide new ideas for changing the "passive" management of patients during hospitalization, "free-range" status after discharge, and solving "difficulty in seeing a doctor".
It fills the gap in the whole process management of perioperative period based on PRO in China
.

The publication of this result will promote the application of a new clinical indicator of patient-reported outcomes (PRO) in the clinical research and clinical practice of malignant tumors in China, and will also establish Sichuan Cancer Hospital's leading position in the field of clinical application of PRO at home and abroad
.
In the next step, the research team will focus on the symptom management model of patients with malignant tumors and other patients based on the "Healthy China 2030" Planning Outline, develop more intelligent key technologies, and demonstrate and promote them in various diseases and regions
.

Author bio

Contributed by: Sichuan Cancer Hospital